Nicholas Fischer
About Nicholas Fischer
Nicholas Fischer is a Biomedical Scientist with extensive experience in nanotechnology and drug delivery systems. He has published over 37 peer-reviewed manuscripts and holds multiple patents in biotechnology, currently leading research at Lawrence Livermore National Laboratory.
Work at Lawrence Livermore National Laboratory
Nicholas Fischer has been employed at Lawrence Livermore National Laboratory since 2008, where he serves as a Biomedical Scientist. His role involves leading research initiatives and projects in the field of biomedical science. Previously, he worked at the same laboratory as a Post-Doctoral researcher from 2005 to 2008, focusing on multifunctional nanoparticle platforms for drug and vaccine delivery applications. His ongoing contributions include developing organ-on-a-chip experimental models and enhancing the cellular composition of central nervous system devices.
Education and Expertise
Nicholas Fischer holds a Ph.D. in Molecular and Cellular Biology from the University of Massachusetts Amherst, which he completed from 2000 to 2005. He also earned a B.S. in Biology and a B.A. in German from West Chester University of Pennsylvania, graduating in 1998. His educational background supports his expertise in biochemistry, nanotechnology, and biotechnology, with a specific focus on nanoparticle platforms and DNA aptamer-based detection strategies.
Research Contributions
Fischer has made significant contributions to the field of biomedical science through his research on multifunctional nanoparticles and their applications in drug and vaccine delivery. He has advanced DNA aptamer-based detection strategies and high-throughput optimization during his post-doctoral research. He has authored over 37 peer-reviewed manuscripts and book chapters, including 12 related to nanoparticle platforms. His work also includes the development of functionalized reconstituted high-density lipoproteins (HDLs) for in vivo applications.
Patents and Innovations
Nicholas Fischer holds two issued patents and has four pending patent applications in the biotechnology sector. His innovations include the development of tunable nanoparticles for enzymatic inhibition and functional control. He currently leads an internally-funded project aimed at enhancing the cellular composition and architecture of an instrumented central nervous system device, reflecting his commitment to advancing biomedical technologies.